| Q38941893 | A multimeric carcinoembryonic antigen signal inhibits the activation of human T cells by a SHP-independent mechanism: a potential mechanism for tumor-mediated suppression of T-cell immunity |
| Q42202658 | A mutation in X-linked inhibitor of apoptosis (G466X) leads to memory inflation of Epstein-Barr virus-specific T cells |
| Q36084979 | A profile of immune response to herpesvirus is associated with radiographic joint damage in rheumatoid arthritis. |
| Q42783189 | Adoptive Immunotherapy after Allogeneic Hematopoietic Progenitor Cell Transplantation: New Perspectives for Transfusion Medicine |
| Q37275304 | Adoptive immunotherapy of cancer using CD4(+) T cells |
| Q37643977 | Analysis of T cell responses during active varicella-zoster virus reactivation in human ganglia |
| Q37457833 | CD4 CTL: living up to the challenge |
| Q41672415 | CD4 T cells specific for a latency-associated γ-herpesvirus epitope are polyfunctional and cytotoxic |
| Q47817879 | CD4+ T cell-mediated cytotoxicity is associated with MHC class II expression on malignant CD19+ B cells in diffuse large B cell lymphoma |
| Q37710793 | Cytolytic CD4 cells: Direct mediators in infectious disease and malignancy |
| Q42261208 | Cytomegalovirus-seropositive children show inhibition of in vitro EBV infection that is associated with CD8+CD57+ T cell enrichment and IFN-γ. |
| Q37597931 | Cytotoxic CD4 T Cells-Friend or Foe during Viral Infection? |
| Q37729167 | Epstein-Barr virus: novel patented therapeutics |
| Q42876926 | Fine tuning and efficient T cell activation with stimulatory aCD3 nanoarrays. |
| Q36641746 | Herpesvirus interference with major histocompatibility complex class II-restricted T-cell activation |
| Q35652539 | Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion |
| Q33496761 | Identification of a human cyclin D1-derived peptide that induces human cytotoxic CD4 T cells |
| Q92151588 | Immune Control and Vaccination against the Epstein-Barr Virus in Humanized Mice |
| Q33289956 | Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy |
| Q60306812 | Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice |
| Q37793222 | Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation |
| Q84953850 | Impairment of CD4+ cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma |
| Q36896712 | Innate and adaptive immunity through autophagy |
| Q58619639 | Interleukins 12 and 15 induce cytotoxicity and early NK-cell differentiation in type 3 innate lymphoid cells |
| Q42059350 | Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 3 inhibits gamma interferon and major histocompatibility complex class II expression |
| Q39787125 | Kinetics of early T cell receptor signaling regulate the pathway of lytic granule delivery to the secretory domain |
| Q39441043 | Longitudinal analysis of frequency and reactivity of Epstein-Barr virus-specific T lymphocytes and their association with intermittent viral reactivation |
| Q39886235 | Monitoring macroautophagy by major histocompatibility complex class II presentation of targeted antigens |
| Q80136124 | NK cells of human secondary lymphoid tissues enhance T cell polarization via IFN-gamma secretion |
| Q37019458 | Patients with Epstein Barr virus-positive lymphomas have decreased CD4(+) T-cell responses to the viral nuclear antigen 1. |
| Q34602196 | Persistent gamma-herpesvirus infection induces a CD4 T cell response containing functionally distinct effector populations |
| Q34170759 | Preformed CD40L is stored in Th1, Th2, Th17, and T follicular helper cells as well as CD4+ 8- thymocytes and invariant NKT cells but not in Treg cells |
| Q24645297 | Priming of protective T cell responses against virus-induced tumors in mice with human immune system components |
| Q39938289 | Protein kinase C theta regulates stability of the peripheral adhesion ring junction and contributes to the sensitivity of target cell lysis by CTL. |
| Q39826214 | Reduced-intensity SCT for chronic active EBV infection: excellent outcomes should trigger future investigations on how EBV-positive recipient cells are eradicated |
| Q36407109 | Repertoire and frequency of immune cells reactive to Epstein-Barr virus-derived autologous lymphoblastoid cell lines |
| Q37773234 | Role of CD4+ cytotoxic T lymphocytes in the control of viral diseases and cancer |
| Q37055402 | Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication |
| Q42221268 | Standardized and highly efficient expansion of Epstein-Barr virus-specific CD4+ T cells by using virus-like particles |
| Q26751016 | The Differentiation and Protective Function of Cytolytic CD4 T Cells in Influenza Infection |
| Q36060423 | The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope |
| Q36382255 | The Tumor Antigen NY-ESO-1 Mediates Direct Recognition of Melanoma Cells by CD4+ T Cells after Intercellular Antigen Transfer. |
| Q39600377 | The endosomal proteome of macrophage and dendritic cells |
| Q33649735 | Transduction of human T cells with a novel T-cell receptor confers anti-HCV reactivity. |
| Q33730171 | Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts |
| Q36602010 | Tumor-specific CD4+ T cells develop cytotoxic activity and eliminate virus-induced tumor cells in the absence of regulatory T cells. |